The Biological Psychiatry Cover Art Initiative: Addressing the under-representation of Black People on the *Journal* cover through a series of commissioned artworks.

John H. Krystal, M.D. (1,2,3,4) Imo Nse Imeh, Ph.D. (5) Rosa P. Garces (6) Nii A. Addy, Ph.D. (7)

- 1. Editor, Biological Psychiatry, New Haven, CT
- 2. Departments of Psychiatry, Neuroscience, and Psychology, Yale University, New Haven, CT
- 3. Psychiatry Services, Yale-New Haven Hospital, New Haven, CT
- 4. Clinical Neuroscience Division, National Center for PTSD, VA Connecticut Healthcare System, West Haven, CT
- 5. Department of Art and Art History, Westfield State University, Holyoke, MA
- 6. Senior Publications Coordinator, Biological Psychiatry, Grapevine, TX
- 7. Departments of Psychiatry and Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT

v.3; 10.4.23

It is a peculiar sensation, this double consciousness, this sense of always looking at one's self through the eyes of others...One ever feels this twoness – an American, a Negro... two warring ideals in one dark body, whose dogged strength alone keeps it from being torn asunder.

W.E.B. DuBois, 1897

https://www.aarp.org/politics-society/history/info-2020/quotes-racial-justice.html

Biological Psychiatry is working to address the under-representation of Black, Indigenous, and People of Color (BIPOC) at all levels of Journal activity, i.e., among the editors, editorial board, reviewers, authors, populations that have been studied in published papers, and the questions asked in published research. Two additional ways that BIPOC individuals have been less visible in the Journal has been in the art depicted in the covers and the artists who created these depictions.

With support of the leadership of the Society of Biological Psychiatry, the *Journal* has a wonderful opportunity to make a clear statement about its commitment to addressing these issues through a very special collaboration with noted artist Dr. Imo Nse Imeh. Each month for the next six months, the *Journal* will publish on its cover an original painting that has been commissioned by the *Journal*, in collaboration with the Society of Biological Psychiatry. The paintings created by Dr. Imeh will address themselves to topics and themes that are central to the *Journal* and the society. The general conceptual framework for the works has emerged from collaborative meetings between the authors of this article. In these generative meetings, we discussed the mission of the *Journal*, the burden of neuropsychiatric disorders, the relationship between racial identity and health disparities, the experiences of illness and disability, and the ways that neuroscience informs our understanding of the causes, courses, and treatments for these disorders.

The *Journal* is thrilled to collaborate with Dr. Imo Nse Imeh on this project. He is a gifted artist and his work is both deeply meaningful and emotionally impactful. Dr. Imeh is a Nigerian-American artist and scholar of African Diaspora art. He is Professor of Art and Art History at Westfield State University in Massachusetts. After graduating from Columbia University, he received M.A. and Ph.D. degrees in Art History from Yale University in 2009. Dr. Imeh's work is informed by his background in historical and philosophical issues related to the black body and cultural identity. His studio art projects interrogate the ways in which black bodies are imagined, represented, ritualized, and transformed by the institutions they inhabit and the imperatives they confront. His work has been recognized by the PBS News Hour and other media outlets.

This has been an inspiring project for all of those involved. We believe that others will be inspired by the art, the process that led to its creation, and its appearance on the cover of a scientific journal associated with a leading scientific society. We plan to present and discuss this work at the annual meeting of the Society of Biological Psychiatry and perhaps other organizations. We hope that this initiative will inspire other scientific journals to follow suit.

## Financial Disclosures:

J.K.: (consultations less than \$5000/yr) Aptinyx, Inc., BioXcel, Biogen, Idec, MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cerevel Pharmaceuticals, Epiodyne, Inc., Esai, Inc., Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., PsychoGenics, Inc., Sunovion Pharmaceuticals, Inc., Takeda Pharmaceuticals (Stock/Options) Biohaven Pharmaceuticals, Cartego Therapeutics, Damona Pharmaceuticals, Delix Therapeutics, Inc., EpiVario, Inc., Freedom Biosciences, Neumora Therapeutics, Inc., Response Pharmaceuticals, Rest Therapeutics, Spring Health, Inc, Tempero Bio, Inc, Terran Biosciences, Tetricus Inc (non-monetary support, i.e., provision of drug) Cerevel Pharmaceuticals, Novartis. Dr. Krystal stands to benefit from patents held by Yale University that were licensed to Janssen Pharmaceuticals (ketamine), Biohaven Pharmaceuticals (riluzole), Freedom Biosciences (NMDA-R antagonist plus MTORC inhibitor), and Spring Health (precision medicine strategy). I.N.I reports no biomedical financial interests or potential conflicts of interest. **R.P.G.** reports no biomedical financial interests or potential conflicts of interest. N.A.A.: This work was funded in part by the State of Connecticut, Department of Mental Health and Addiction Services, but this publication does not express the views of the Department of Mental Health and Addiction Services or the State of Connecticut. The views and opinions expressed are those of the authors. Royalties: Tyndale House Publishers. Speakers Bureau/ Consultation Fees: American Program Bureau.